Drug combo shows promise in slowing rare sarcomas
NCT ID NCT03114527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests two oral drugs, ribociclib and everolimus, in people with advanced dedifferentiated liposarcoma or leiomyosarcoma who have had at least one prior treatment. The goal is to see if the combination can stop or slow tumor growth. About 48 participants will take the drugs daily in cycles, and their tumors will be scanned regularly to measure response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ribociclib and everolimus (two oral cancer drugs)
What this could lead to
If successful, this combination could offer a new treatment option to slow tumor growth in people with advanced soft tissue sarcomas who have already tried other therapies.
What could go wrong
This is a small, early-phase trial (48 participants) with no placebo group. The drugs may cause side effects like mouth sores, fatigue, or lung inflammation, and may not work for all sarcoma types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States